ISS X: Breaking Barriers in Platinum-Resistant Ovarian Cancer: Novel Targets and Emerging Therapies
Supporting Company: Prime Education, LLC
Date: Sunday, April 12, 2026
Time: 7:00 a.m. – 8:30 a.m.
Location: Room 209
Faculty:
- Kathleen N. Moore, MD, Deputy Director & Director of Phase 1 Studies Fred & Pamela Buffett Cancer Center at the University of Nebraska Medical Center Omaha, NE
- Elizabeth (Betsy) Lee, MD, Division of Gynecologic Oncology & Center for Cancer Therapeutic Innovation, Dana-Farber Cancer Institute, Boston, Massachusetts
Moderator: Michael R Stinchon, Jr, RPh, Associate Director, Optum Rx Programs- Formulary Strategy and Trend Management, Avon, CT
Description: Platinum-resistant ovarian cancer (PROC) remains a major clinical challenge, marked by limited effective therapies and an urgent need for novel, targeted approaches to overcome treatment resistance and improve patient outcomes.
Join two leading ovarian cancer experts for this live and livestreamed symposium at the SGO 2026 Annual Meeting on Women’s Cancer, delivering a focused update on current therapeutic limitations and the rapidly evolving treatment landscape in PROC.
This 1.5-hour interactive session will feature:
- A 2D animation illustrating mechanisms of action and therapeutic rationale for emerging FRα- and CDH6-directed antibody-drug conjugates (ADCs) and glucocorticoid receptor (GR) modulators
- The latest clinical trial data and evolving guidance informing the use of novel targeted therapies in PROC, including biomarker-driven treatment selection and class-specific adverse event management
- Expert insights into integrating biomarker testing into clinic workflows to support individualized treatment planning
- Introduction of the PROC Clinical Trial Pocket Guide to facilitate timely clinical trial referral
- An interactive live Q&A enabling direct discussion of real-world clinical challenges and decision points with expert faculty
Strengthen your clinical confidence and stay ahead of emerging advances as experts translate cutting-edge evidence into practical strategies for managing platinum-resistant ovarian cancer.
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by independent medical education grants from Genmab and Corcept Therapeutics Incorporated.
ISS XI: A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer
Supporting Company: GSK
Date: Sunday, April 12, 2026
Time: 1:30 p.m. – 3:00 p.m.
Location: Ballroom B
Faculty: Sharyn Lewin, MD, FACOG, FACS, Director at Holy Name
Description:
- Endometrial Cancer Background
- Review the incidence of endometrial cancer and the importance of MMR/MSI biomarker testing
- RUBY Part 1 Trial Results
- Learn about the efficacy and safety data for JEMPERLI in combination with carboplatin and paclitaxel followed by JEMPERLI as a single agent for primary advanced or recurrent endometrial cancer from the RUBY Part 1 trial
- Important Safety Information
- Review the Important Safety Information for JEMPERLI
- Summary
ISS XII: Cases and Conversations™: Redefining Treatment Pathways in Low-Grade Serous Ovarian Cancer
Supporting Company: Physicians Education Resource LLC (PER)
Date: Sunday, April 12, 2026
Time: 1:30 p.m. – 3:00 p.m.
Location: Room 208
Chair: Rachel N. Grisham, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Faculty:
- David M. Gershenson, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
- Ursula A. Matulonis, MD, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston MA
- David M. O’Malley, MD, The Ohio State University and the James Comprehensive Cancer Center, Columbus, OH
Description: Low-grade serous ovarian cancer (LGSOC) is a rare, distinct subtype of epithelial ovarian cancer that disproportionately affects younger women and remains challenging to treat due to its slow progression, high recurrence risk, and limited responsiveness to chemotherapy. With the rapidly evolving landscape of targeted therapies—including recent advances in RAF/MEK pathway inhibitors—clinicians face increasing complexity in diagnosis, molecular interpretation, and treatment selection, highlighting a significant unmet educational need. To address these gaps, this program will use the Cases and Conversations™ format to deliver an interactive, case-based discussion led by expert faculty. Presented adjunct to the 2026 SGO Annual Meeting on Women’s Cancer in San Juan, this hybrid symposium provides an ideal forum for translating new clinical trial data, molecular insights, and evolving standards of care into real-world practice. The format is designed to help clinicians contextualize emerging evidence, compare decision-making with peers and experts, and strengthen their ability to personalize therapy for patients with LGSOC.
ISS XIII: Expert Second Opinion: Investigators Provide Perspectives on the Best-Practice Management of Ovarian Cancer
Supporting Company: Research To Practice
Date: Sunday, April 12, 2026
Time: 1:30 p.m. – 3:00 p.m.
Location: Ballroom A
Faculty:
- Nicoletta Colombo, MD – Director, Gynecologic Oncology Program, European Institute of Oncology IRCCS, University of Milano-Bicocca, Milan, Italy
- Gottfried E Konecny, MD – Professor of Medicine and Ob/Gyn , Director, Medical Gynecologic Oncology, Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
Moderator: Shannon N. Westin, MD, MPH, FASCO, FACOG – Professor, Medical Director, Gynecologic Oncology Center, Director, Early Drug Development, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas, MD Anderson Cancer Center
Houston, Texas
Additional faculty to be announced.
Description: This 1.5-hour CME-accredited symposium, developed by Research To Practice (RTP), will focus on ovarian cancer, The faculty panel will comprise four clinical investigators, one of whom will moderate the session. In advance of the conference, RTP will also recruit two additional investigators to participate in one-on-one interviews with RTP President, Dr. Neil Love, during which they will present challenging or interesting cases from their practices of patients with ovarian cancer for which they would seek input or a second opinion. Excerpts from each interview will be selected for presentation during the symposium in accordance with the defined educational objectives. The agenda for the satellite symposium will be divided into 4 modules, each consisting of extensive panel discussion reviewing the video case presentations followed by an 8-minute didactic lecture reviewing recent data sets, current management approaches and ongoing trials relevant to the care of patients with ovarian cancer. To enhance engagement, attendees will be invited to submit their own questions for faculty discussion. The program will also be webcast live, allowing virtual attendees to participate in the proceedings in real time.
This CME program is accredited by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.
ISS XIV: Data + Perspectives: The Potential Role of TROP2- and CDH6-Directed Antibody-Drug Conjugates in Gynecologic Cancers
Supporting Company: Research To Practice
Date: Sunday, April 12, 2026
Time: 1:30 p.m. – 3:00 p.m.
Location: Room 209
Faculty:
- Ramez N. Eskander, MD – Julie St. John Endowed Chair in Gynecologic Oncology, Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Clinical Trials Office Medical Director, Fellowship Director – Gynecologic Oncology, UC San Diego Health Rebecca and John Moores NCI-Designated Comprehensive Cancer Center, San Diego, California
- Bradley J. Monk, MD – Medical Director, Late-Phase Research Program, Florida Cancer Specialists & Research Institute, Vice President and Member, Board of Directors, GOG Foundation, Co-Director, GOG Partners, West Palm Beach, Florida
Moderator: Kathleen N. Moore, MD, MS – Deputy Director, Co-Director, Cancer Therapeutics Program, Stephenson Cancer Center at OU Health, Professor, Gynecologic Oncology, University of Oklahoma HSC, Board of Directors, GOG Foundation, Board of Directors, ASCO, Oklahoma City, Oklahoma
Description: This 1.5-hour CME-accredited symposium, developed by Research To Practice (RTP), will focus on the potential role of TROP2- and CDH6-directed antibody-drug conjugates (ADCs) in the management of patients with gynecologic cancers, The faculty panel will comprise three clinical investigators, one of whom will moderate the session. Leading up to the event, each faculty member will provide a number of interesting cases of patients with ovarian, endometrial or cervical cancer appropriate for or treated with a novel TROP2- or CDH6-directed ADC as part of a clinical research study. To set the stage for discussion and debate, at the beginning of each of the 3 modules, one of the faculty members will present a case from his/her practice. Each case discussion will attempt to frame a handful of educational issues and allow the faculty to describe how they currently think through the potential future use of these agents in various clinical situations. Following the case-based discussion, a faculty member will deliver a presentation reviewing relevant scientific knowledge, available data sets and ongoing research studies related to the topics under review. To enhance engagement, attendees will be invited to submit their own questions for faculty discussion. The program will also be webcast live, allowing virtual attendees to participate in the proceedings in real time.
This CME program is accredited by Research To Practice and supported by educational grants from Daiichi Sankyo Inc., Gilead Sciences Inc., and Merck.
ISS XV: Lynparza Trivia Challenge: How Well Do You Know the Maintenance Therapy Landscape in Advanced Ovarian Cancer?
Supporting Company: AstraZeneca
Date: Monday, April 13, 2026
Time: 7:30 a.m. – 9:00 a.m.
Location: Room 208
Faculty: Sharyn Lewin, MD, FACOG, FACS, Director at Holy Name
Description: The Ovarian Cancer Trivia Deck is an interactive, trivia-style presentation that highlights data from key LYNPARZA clinical trials. Attendees are invited to participate in thought-provoking trivia questions designed to both challenge and expand their knowledge of the subject.
ISS XVI: Navigating the Winds of Progress: Plotting a Course for Immunotherapy in Endometrial Cancer
Supporting Company: GSK
Date: Monday, April 13, 2026
Time: 7:30 a.m. – 9:00 a.m.
Location: Room 209
Faculty: TBD
Description:
- Evaluate the clinical outcomes of dostarlimab and chemotherapy followed by dostarlimab maintenance in the mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer (EC) population, including long-term survival and safety
- Explore data supporting the use of immunotherapy and chemotherapy in patients with mismatch repair proficient (MMRp) primary advanced or recurrent EC
- Discuss the timing and patterns of immune related adverse events (irAEs) of dostarlimab and review management strategies
ISS XVII: Show Me the Data®: Evolving Standards and New Frontiers in Ovarian Cancer
Supporting Company: Physicians Education Resource LLC (PER)
Date: Monday, April 13, 2026
Time: 7:30 a.m. – 9:00 a.m.
Location: Ballroom B
Faculty: Kathleen N. Moore, MD, MS, FASCO, Alexandra Leary, MD, PhD, Bradley Monk, MD
Description:
Join leading experts in gynecologic oncology for this interactive 90-minute satellite symposium exploring the latest advances in ovarian cancer treatment. Through case-based panel discussions using the signature “Show Me the Data” format, faculty will guide attendees through critical decision points in ovarian cancer management — from optimizing molecular testing strategies and biomarker-driven therapy selection to integrating next-generation antibody-drug conjugates, PARP inhibitors, and immune checkpoint inhibitors into clinical practice.
Key Topics Include:
- The role of germline, somatic, and HRD testing in personalizing treatment
- First-line therapy and maintenance strategies incorporating PARPi and immunotherapy combinations
- Emerging ADCs and novel agents for platinum-resistant ovarian cancer
- Practical strategies for adverse event management and toxicity monitoring
- Addressing disparities in access to biomarker testing and novel therapies
Attendees will engage with faculty through live audience polling at each clinical decision point, followed by expert data presentations and multidisciplinary panel discussions. This activity is designated for 1.5 AMA PRA Category 1 Credits™ and 1.5 nursing contact hours. The symposium will also be archived as a chaptered online enduring activity available for 12 months following the live event.
